-
公开(公告)号:US20240148715A1
公开(公告)日:2024-05-09
申请号:US18506944
申请日:2023-11-10
发明人: Eva Maria BECKER-PELSTER , Hanna TINEL , Michael HAHN , Dieter LANG , Gerrit WEIMANN , Johannes NAGELSCHMITZ , Lisa DIETZ , Soundos SALEH , David JUNG , Ildiko TEREBESI , Tobias MUNDRY , Annett RICHTER , Britta OLENIK , Birgit KEIL , Bernd RÖSLER , Peter FEY , Heiko SCHIRMER , Guido BECKER , Clemens BOTHE , Helene FABER , Julian EGGER , Mark PARRY , David WARD , Cecile VITRE
CPC分类号: A61K31/47 , A61K9/0075 , A61P9/12
摘要: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 μg, preferably 480 to 2000 μg of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably in form of monohydrate I of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid in form of mono hydrate (II) of formula (I-M-II), is administered to a patient in need thereof once or twice daily for a period of at least two consecutive days, preferably at least 2 to 7 consecutive days, preferably for a period of at least 14 consecutive days, in particular from after onset of treatment for the whole course of the disease, wherein the inhalative dosage form preferably comprises the combination of the active ingredient and a pharmaceutically suitable excipient or carrier, while preferably the active ingredient and a pharmaceutically suitable excipient are filled in a hard capsule.
-
公开(公告)号:US20240116874A1
公开(公告)日:2024-04-11
申请号:US18506737
申请日:2023-11-10
发明人: Britta OLENIK , Birgit KEIL , Bernd RÖSLER , Peter FEY , Heiko SCHIRMER , Guido BECKER , Julian EGGER , Clemens BOTHE , Helene FABER
IPC分类号: C07D215/48 , A61K9/00 , A61P9/12 , A61P11/08
CPC分类号: C07D215/48 , A61K9/0075 , A61P9/12 , A61P11/08
摘要: The present invention relates to a novel and improved process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluo-romethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of the formula (I) and to novel crystalline forms of it, which is i.a. the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), furthermore the present invention relates to a novel and selective crystallization process for preparation of the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), preferably monohydrate I of formula (I-M-I) and to pharmaceutical compositions comprising monohydrate I of formula (I-M-I) and to its use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiopulmonary and cardiovascular diseases.
-
公开(公告)号:US20200237648A1
公开(公告)日:2020-07-30
申请号:US16486449
申请日:2019-07-19
发明人: ANKE STROYER , Carmen LOBBACK , Peter SERNO , Kia LOVIS , Philipp RUBENBAUER , Helko SCHIRMER , Danja GROßBACH , Tia JACOBS , Britta OLENIK , Julia Küsel , Donald BIERER
IPC分类号: A61K9/00 , A61K9/20 , A61K31/196
摘要: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal, pulmonary and ophthalmic disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
4.
公开(公告)号:US20170260140A1
公开(公告)日:2017-09-14
申请号:US15509600
申请日:2015-09-07
发明人: Hartmut BECK , Tobias THALER , Raimund KAST , Daniel MEIBOM , Mark MEININGHAUS , Carsten TERJUNG , Martina DELBECK , Klemens LUSTIG , Uwe MUENSTER , Britta OLENIK
IPC分类号: C07D215/52 , C07D401/04 , C07D215/60 , C07D401/12
CPC分类号: C07D215/52 , C07D215/60 , C07D401/04 , C07D401/12
摘要: The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.
-
公开(公告)号:US20160289220A1
公开(公告)日:2016-10-06
申请号:US15035165
申请日:2014-11-05
发明人: Britta OLENIK , Birgit KEIL , Martin-Holger HINZ , Chantal FURSTNER , Mario JESKE , Jens ACKERSTAFF
IPC分类号: C07D413/04 , C07C229/26
CPC分类号: C07D413/04 , C07C229/26
摘要: Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid of the formula (I), in particular amino acid salts such as the lysine salt and alkali metal salts such as the sodium salt and the potassium salt, processes for their preparation, medicaments comprising them and their use for controlling diseases.
摘要翻译: 1-(3-甲基-2-氧代-2,3-二氢-1,3-苯并恶唑-6-基)-2,4-二氧代-3 - [(1R)-4-(三氟甲基)-2 ,3-二氢-1H-茚-1-基] -1,2,3,4-四氢嘧啶-5-甲酸,特别是氨基酸盐如赖氨酸盐和碱金属盐,如 作为钠盐和钾盐,其制备方法,包含它们的药物及其用于控制疾病的用途。
-
6.
公开(公告)号:US20190002409A1
公开(公告)日:2019-01-03
申请号:US16125645
申请日:2018-09-07
发明人: Hartmut BECK , Tobias THALER , Raimund KAST , Daniel MEIBOM , Mark MEININGHAUS , Carsten TERJUNG , Martina DELBECK , Klemens LUSTIG , Uwe MUENSTER , Britta OLENIK
IPC分类号: C07D215/52 , C07D401/04 , C07D215/60 , C07D401/12
CPC分类号: C07D215/52 , C07D215/60 , C07D401/04 , C07D401/12
摘要: The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.
-
公开(公告)号:US20180036300A1
公开(公告)日:2018-02-08
申请号:US15552997
申请日:2016-03-15
发明人: Hartmut BECK , Tobias THALER , Raimund KAST , Mark MEININGHAUS , Carsten TERJUNG , Uwe MUENSTER , Britta OLENIK
IPC分类号: A61K31/47 , C07D409/04 , C07D215/52 , C07D405/12 , A61K31/16 , A61K31/195
CPC分类号: A61K31/47 , A61K31/16 , A61K31/195 , C07D215/52 , C07D405/12 , C07D409/04
摘要: The present application relates to novel substituted N-bicyclo-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
-
公开(公告)号:US20210179541A1
公开(公告)日:2021-06-17
申请号:US16767724
申请日:2018-11-26
发明人: Peter FEY , Philipp RUBENBAUER , Kai LOVIS , Britta OLENIK , Julia KUSEL , Felix SPINDLER
IPC分类号: C07C233/88 , C07C231/02 , C07C231/12 , C07C51/09 , C07C227/18
摘要: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
-
公开(公告)号:US20180155336A1
公开(公告)日:2018-06-07
申请号:US15568575
申请日:2016-05-02
发明人: Franz-Josef MAIS , Werner HEILMAN , Britta OLENIK , Birgit KEIL , Guido BECKER , Daniel MEIBOM , Thomas KUHLMANN
IPC分类号: C07D417/12
CPC分类号: C07D417/12 , A61K47/64 , C07K5/06026
摘要: The present application relates to a novel and improved process for preparing the compound 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-L-alanyl L-alaninate monohydrochloride of the formula (I) to novel precursors for its preparation, and to the preparation and use of crystal modification I of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}-ethyl-L-alanyl L-alaninate monohydrochloride of the formula (I).
-
公开(公告)号:US20240174633A1
公开(公告)日:2024-05-30
申请号:US18549281
申请日:2022-03-04
发明人: Guillaume LEVILAIN , Tia JACOBS , Britta OLENIK , Franco RUBINO , Krischan ZIEM , Michal SOWA , Susanne RÖHRIG
IPC分类号: C07D401/10
CPC分类号: C07D401/10
摘要: The present invention relates to crystalline forms of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide which are the crystalline modification I and the crystalline modification II, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
-
-
-
-
-
-
-
-
-